We are searching for:
clinical phase projects with efficacy signal, registered or marketed products

Territory:
Europe, Russia and Commonwealth of Independent States (CIS), China, Latin-America, Australia

 

Throughout our licensing activities and during our long-term partnerships we are devoted to strengthen the collaboration with our value of innovation, stability, ethics and teamwork which have been the essence of the company since its foundation.
Starting from the first contact followed by pre-evaluation, due diligence, negotiation and execution of an agreement, our utmost goal is to maximize the know-how and expertise of both companies in order to deliver products that best meet the expectations of the stakeholder.
We believe that continuous support, knowledge-sharing and alliance management leads to a successful collaboration that helps parties to enhance their R&D and business. We believe that continuous support, knowledge-sharing and alliance management leads to a successful collaboration that helps parties to enhance their R&D and business. Our strengths and capabilities:
  • Original research on the field of CNS and Women’s Healthcare
  • Among top Women’s Healthcare companies with wide range of portfolio
  • Generic and API development in several countries
  • API & FDF manufacturing with 8 manufacturing sites globally
  • Own sales & marketing, distribution network in 51 countries
  • Over 3.000 specialized sales representatives and key account managers in Europe, Russia and CIS countries, China, Latin-America and Australia
  • Strong relationship with specialists and GPs
  • Regulatory affairs, extensive knowledge and expertise in local and central regulations
  • Excellent relationships with health authorities
  • Health Technology Assessment team supporting pricing and reimbursement process
  • Long-term partnerships with key medical societies in our focus areas

The evaluation and pursuit of partnering opportunities are performed by the Global Portfolio Development, Licensing & Strategic Pricing department at Budapest, in our headquarters.

The initial phase, Search & Identify begins with the exploration and identification of business opportunities that are in accordance with the Company’s strategic goals.

During the Assessment phase the evaluation of non-confidential information takes place. In the event the proposed opportunity is consistent with Richter’s strategic goals, feedback will be provided regarding the decision on pursuing the asset.

The complete exploration of the opportunity will take place via Due Diligence, during which all vital parameters, including but not limited to medical, regulatory, commercial and pharmaco-economic properties, will be thoroughly investigated by our internal experts.

Once the commercial viability of the proposed opportunity is deemed positive, Negotiations will take place to lay down fundamental collaboration details in pursuit of reaching final agreement.

Richter pays special attention to the role of Alliance Management by assuring that projects are managed properly and commitments are fulfilled in order to strengthen and enhance a successful partnership.